title: Improved detection of medullary thyroid cancer with radiolabeled antibodies to carcinoembryonic antigen.
abstract: OBJECTIVE
  This investigation was undertaken to assess the targeting of established and occult medullary thyroid cancer (MTC) with radiolabeled monoclonal antibodies (MAbs) reactive with carcinoembryonic antigen (CEA).
  
  
  METHODS
  Twenty-six assessable patients with known (n = 17) or occult (n = 9) MTC were studied with radiolabeled anti-CEA MAbs. Scintigraphic images were collected to determine targeting of tumor lesions.
  
  
  RESULTS
  The targeting results of technetium 99m (99mTc)-,iodine 123 (123I)-, and iodine 131 (131I)-labeled anti-CEA antibodies (all directed against the same epitope of CEA) indicated that all these reagents were capable of detecting established and occult MTC. The sensitivity for detection of known sites of disease ranged from 76% to 100% for the various anti-CEA MAbs used, when compared with computed tomography (CT), magnetic resonance imaging (MRI), bone scan, or other imaging modalities. Moreover, the antibody scan was positive in seven of nine patients with occult disease (patients with negative conventional imaging studies, but who had elevated calcitonin and/or CEA levels). Three of seven patients underwent surgery and the disease was confirmed by histopathology in all three.
  
  
  CONCLUSIONS
  Anti-CEA MAbs are excellent agents for imaging recurrent, residual, or metastatic MTC. The high lesion sensitivity in patients with known lesions, combined with the ability to detect disease, may make these agents ideal for staging patients, monitoring disease pretherapy or posttherapy, and especially for evaluating patients with recurrent or persistent hypercalcitonemia or CEA elevations after primary surgery. Analogous to radioiodine in the evaluation of patients with differentiated thyroid cancer, radiolabeled anti-CEA MAbs may achieve a similar role in diagnosing and monitoring patients with MTC.
authors.affiliation: Garden State Cancer Center at the Center for Molecular Medicine and Immunology, Newark, NJ, USA.
authors.forename: M
authors.initials: M
authors.lastname: Juweid
authors.forename: R M
authors.initials: RM
authors.lastname: Sharkey
authors.forename: T
authors.initials: T
authors.lastname: Behr
authors.forename: L C
authors.initials: LC
authors.lastname: Swayne
authors.forename: A D
authors.initials: AD
authors.lastname: Rubin
authors.forename: T
authors.initials: T
authors.lastname: Herskovic
authors.forename: D
authors.initials: D
authors.lastname: Hanley
authors.forename: A
authors.initials: A
authors.lastname: Markowitz
authors.forename: R
authors.initials: R
authors.lastname: Dunn
authors.forename: J
authors.initials: J
authors.lastname: Siegel
authors.forename: T
authors.initials: T
authors.lastname: Kamal
authors.forename: D M
authors.initials: DM
authors.lastname: Goldenberg
mesh_terms: D002272:Carcinoembryonic Antigen / Q000276:immunology*; D018276:Carcinoma, Medullary / Q000000981:diagnostic imaging* / Q000276:immunology*; D006801:Humans; D007457:Iodine Radioisotopes; D011237:Predictive Value of Tests; D011877:Radionuclide Imaging; D012680:Sensitivity and Specificity; D013667:Technetium; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging* / Q000276:immunology*
chemical_list: D002272:Carcinoembryonic Antigen; D007457:Iodine Radioisotopes; D013667:Technetium